Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Assets (2021 - 2025)

ARS Pharmaceuticals' Current Assets history spans 5 years, with the latest figure at $284.9 million for Q4 2025.

  • For Q4 2025, Current Assets fell 14.78% year-over-year to $284.9 million; the TTM value through Dec 2025 reached $284.9 million, down 14.78%, while the annual FY2025 figure was $284.9 million, 14.78% down from the prior year.
  • Current Assets for Q4 2025 was $284.9 million at ARS Pharmaceuticals, down from $338.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $378.3 million in Q1 2021 and bottomed at $60.7 million in Q4 2021.
  • The 5-year median for Current Assets is $269.1 million (2022), against an average of $268.9 million.
  • The largest YoY upside for Current Assets was 357.27% in 2022 against a maximum downside of 30.93% in 2022.
  • A 5-year view of Current Assets shows it stood at $60.7 million in 2021, then skyrocketed by 357.27% to $277.7 million in 2022, then dropped by 16.56% to $231.7 million in 2023, then soared by 44.26% to $334.3 million in 2024, then dropped by 14.78% to $284.9 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Current Assets are $284.9 million (Q4 2025), $338.9 million (Q3 2025), and $281.4 million (Q2 2025).